Disease: Paroxysmal nocturnal hemoglobinuria
- <em>Candida krusei</em> pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report
- A case of paroxysmal cold hemoglobinuria complicated by latent syphilis
- A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience
- Abnormal expression of CUX1 influences autophagy activation in paroxysmal nocturnal hemoglobinuria
- Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial
- Adenovirus-associated Paroxysmal Cold Hemoglobinuria as Chilly Month Hemolytic Crisis
- Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment
- Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management
- Biomimetic proteolipid vesicles for reverting GPI deficiency in paroxysmal nocturnal hemoglobinuria
- Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors
- C5 inhibition in PNH: still effective and safe
- Candida krusei pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report
- Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria
- Case report: Paroxysmal nocturnal hemoglobinuria presenting with hemorrhagic esophageal varices
- Challenges in recognising paroxysmal cold hemoglobinuria
- Classic paroxysmal nocturnal haemoglobinuria presenting with intestinal malabsorption syndrome, acute abdomen and acute kidney injury
- Clinical characteristics of aplastic anemia patients with abnormal autoantibodies and the impact of autoantibodies on immunosuppressive therapy response
- Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy
- Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes
- Complement in human disease: approved and up-and-coming therapeutics
- Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
- Correction to: Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison
- Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
- COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study
- Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)
- Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan
- Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis
- Early Mortality in Paroxysmal Nocturnal Hemoglobinuria
- Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China
- Eculizumab Treatment of Massive Hemolysis Occurring in a Rare Co-Existence of Paroxysmal Nocturnal Hemoglobinuria and Myasthenia Gravis
- Editorial: Practical recommendations and consensus for the management of immune mediated hematologic diseases
- Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis
- Efficacy, Safety and Quality of Life of Pegcetacoplan in Japanese Patients With Paroxysmal Nocturnal Hemoglobinuria Treated Within the Phase 3 PEGASUS Trial
- Erratum: Candida krusei pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report: erratum
- Evaluation of the impact of two C5 genetic variants on C5-eculizumab complex stability at the molecular level
- Expert consensus on clonal screening and monitoring of complement inhibitor therapy in paroxysmal nocturnal hemoglobinuria (2024)
- Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks
- FLAER as a standalone reagent for paroxysmal nocturnal hemoglobinuria: Do we need to reconsider the guidelines for testing?
- Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
- Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
- Hemosiderin induced acute kidney injury requiring hemodialysis in patients with paroxysmal nocturnal hemoglobinuria: A case report
- How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria
- Identification of Paroxysmal Nocturnal Hemoglobinuria-Type Bone Marrow Mast Cells
- Immune pathophysiology of bone marrow failure
- Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry
- Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report
- Kidney R2* Mapping for Noninvasive Evaluation of Iron Overload in Paroxysmal Nocturnal Hemoglobinuria
- Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature
- Long-term effectiveness of eculizumab: Data from the International PNH Registry
- Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea
- Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH
- Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
- Manifestation of Pancytopenia Associated with COVID-19 as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Aplastic Anemia (AA)
- Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants?
- Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria
- Non-capsulated <em>Neisseria</em> meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
- Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
- Novel therapeutic agents for hemolytic anemia
- Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
- Paroxysmal Nocturnal Hemoglobinuria
- Paroxysmal nocturnal hemoglobinuria in a patient post COVID-19 virus infection: A case report with literature review
- Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043 patient/years analysis
- Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment
- Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations
- Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape
- Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
- Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria
- Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia
- Plain language summary on long-term effectiveness of eculizumab: Data from the International PNH Registry
- Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?
- Pozelimab: First Approval
- Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
- Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)
- Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review
- Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
- RNA therapeutics for disorders of excretory system
- Role and clinical significance of MUC4 gene mutations in thrombotic events in patients with classic paroxysmal nocturnal hemoglobinuria
- Role of <em>PIGM</em> and <em>PIGX</em> in glycosylphosphatidylinositol biosynthesis and human health (Review)
- Role of complement in myasthenia gravis
- Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
- Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
- Several implications for the pathogenesis and treatment of thrombosis in PNH patients according to multiomics analysis
- Severe Acute Kidney Injury in Children as a Rare Complication of Paroxysmal Cold Hemoglobinuria
- Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long-term aplastic anemia treatment
- Successful Treatment of Warm Autoimmune Hemolytic Anemia with a Positive Donath-Landsteiner Test Using Rituximab
- The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment
- The Features of COVID-19's Course and the Efficacy of the Gam-COVID-Vac Vaccine in Patients with Paroxysmal Nocturnal Hemoglobinuria
- The immunologic abnormalities in patients with paroxysmal nocturnal hemoglobinuria are associated with disease progression
- The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells
- The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy
- The monosialoganglioside GM1a protects against complement attack
- The role of anticomplement therapy in the management of the kidney allograft
- Thrombocytopenia
- Transformation of aplastic anemia with paroxysmal nocturnal hemoglobinuria clone to childhood B-cell precursor acute lymphoblastic leukemia
- Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria
- Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis
- Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways
- Uncovering the Genetic Etiology of Inherited Bone Marrow Failure Syndromes Using a Custom-Designed Next-Generation Sequencing Panel